Disease progression model using the integrated Alzheimer's Disease Rating Scale-Reference-Cited by-同舟云学术

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Published:2022-11-30 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Gueorguieva Ivelina¹,Chua Laiyi²,Willis Brian A.²,Sims John R.²,Wessels Alette M.²

Affiliation:

1. Eli Lilly and Company Bracknell UK

2. Eli Lilly and Company Indianapolis Indiana USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12876

Reference32 articles.

1. Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative

2. Suitability of the Clinical Dementia Rating‐Sum of Boxes as a single primary endpoint for Alzheimer's disease trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the impact of slowing disease progression for individuals with biomarker-confirmed early symptomatic Alzheimer’s disease;Current Medical Research and Opinion;2024-09

2. Coupling quantitative systems pharmacology modelling to machine learning and artificial intelligence for drug development: its pAIns and gAIns;Frontiers in Systems Biology;2024-07-12

3. How donanemab data address the coverage with evidence development questions;Alzheimer's & Dementia;2024-02-07

4. Donanemab in Early Symptomatic Alzheimer Disease;JAMA;2023-08-08

5. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2023-04